| http://purl.uniprot.org/citations/12673206 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/12673206 | http://www.w3.org/2000/01/rdf-schema#comment | "B-Myb is a widely expressed member of the myb oncogene family that has been shown to act as either an activator or repressor of gene transcription in a cell-type-specific fashion. For example, in aortic smooth muscle cells B-Myb represses transcription of the alpha2(V) collagen gene. Recently, phosphorylation of B-Myb by cyclin A was shown to enhance greatly its ability to transactivate. Here, we have tested the effects of cyclin A on the ability of B-Myb to repress. We report that coexpression of cyclin A abolished repression of the alpha2(V) collagen promoter, whereas a dominant-negative cyclin-dependent kinase 2 (cdk2) enhanced repression by ectopic and endogenous B-Myb protein. Mutation of 10 of 22 putative cyclin A sites, which greatly reduces the effects of cyclin A on transactivation by B-Myb, had no effect on the ability of cyclin A to alleviate B-Myb-mediated repression of alpha2(V) collagen promoter activity. Furthermore, the stability of the mutant B-Myb protein was largely unaffected by cyclin A, although ectopic expression of cyclin A enhanced the rate of decay of wild-type B-Myb protein. Thus, the mechanisms of repression and activation appear distinct, for example, mediated by different critical phosphorylation sites or protein-protein interactions. B-Myb mutants with either deletion of aa 374-581 (B-Myb-Mut3) or C-terminal truncation beyond aa 491 (B-Myb-491) positively regulated alpha2(V) collagen promoter activity, and were not affected by cyclin A. Thus, our findings indicate that the ability of B-Myb to function as a repressor of matrix promoter activity is abolished by cyclin A, and maps the sites mediating negative regulation by B-Myb to the region between aa 491 and 582."xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://purl.org/dc/terms/identifier | "doi:10.1038/sj.onc.1206231"xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://purl.uniprot.org/core/author | "Lewis R.E."xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://purl.uniprot.org/core/author | "Sonenshein G.E."xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://purl.uniprot.org/core/author | "Petrovas C."xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://purl.uniprot.org/core/author | "Jeay S."xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://purl.uniprot.org/core/date | "2003"xsd:gYear |
| http://purl.uniprot.org/citations/12673206 | http://purl.uniprot.org/core/name | "Oncogene"xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://purl.uniprot.org/core/pages | "2011-2020"xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://purl.uniprot.org/core/title | "B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain."xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://purl.uniprot.org/core/volume | "22"xsd:string |
| http://purl.uniprot.org/citations/12673206 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/12673206 |
| http://purl.uniprot.org/citations/12673206 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/12673206 |
| http://purl.uniprot.org/uniprot/#_P10244-mappedCitation-12673206 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/12673206 |
| http://purl.uniprot.org/uniprot/#_P20248-mappedCitation-12673206 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/12673206 |
| http://purl.uniprot.org/uniprot/P10244 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/12673206 |
| http://purl.uniprot.org/uniprot/P20248 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/12673206 |